Post-op prednisone vs standard steroid regimen after knee or hip replacement

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 trial compares a 5-day high-dose oral prednisone regimen (40 mg daily) to the standard intraoperative steroid approach following unicompartmental knee arthroplasty or total hip arthroplasty. Outcomes include postoperative pain, swelling, range of motion, opioid use, and continuous glucose monitoring. The study uses prednisone alongside continuous glucose monitoring and InkWell Health Tattoos for data collection at Columbia University Irving Medical Center. Eligible participants are adults undergoing planned surgery at CUIMC and managed by Dr. Roshan P. Shah, excluding those with recent steroid or narcotic exposure, pregnancy, uncontrolled diabetes, or lack of smartphone access. The trial is sponsored by Columbia University with collaboration from the Orthopaedic Scientific Research Foundation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* MUST BE CONTACTED BY THE STUDY TEAM TO BE PART OF THE STUDY. No applications taken
* Undergoing Primary Unicompartmental Knee Arthroplasty or Total Hip Arthroplasty
* Age 18 and above
* Patient at Columbia University Irving Medical Center and be undergoing planned surgery by Dr. Roshan P. Shah

Exclusion Criteria:

* Steroid therapy
* Narcotic use within past 3 months
* History of corticosteroid intolerance
* Pregnancy
* Uncontrolled diabetes
* Doesn't own smart phone

Drop Criteria:

\- 2nd dose of IV dexamethasone

Where it's running

• Columbia University Irving Medical Center
  New York, New York, United States Recruiting

Study contacts

• Study coordinator: Jacqueline Lenahan
• Email: jl5092@cumc.columbia.edu
• Phone: (212) 305-8193

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Suzetrigine for pain control after primary total hip replacement

  This will test whether taking Suzetrigine before surgery and for seven days afterward reduces opioid use and improves pain control in adults having a primary total hip replacement.

  Recruiting Phase 3 Hospital for Special Surgery, New York · New York, New York · NCT07226700

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Autologous adipose-derived stem cell injections for knee osteoarthritis

  We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.

  Recruiting at 3 sites Yonsei University · Incheon and 2 other locations · NCT07901790

• Early wear of a Vitamin E-infused liner in a dual-mobility hip replacement

  This study tests whether a Vitamin E-infused liner in a dual-mobility hip implant wears as little as a conventional liner over two years in adults needing hip replacement.

  Recruiting Phase 4 Uppsala University · Uppsala, Uppsala County · NCT07863557

• Preoperative Music to Ease Anxiety Before Hip or Knee Replacement

  Patients awaiting hip or knee replacement listen to their own music through noise‑canceling headphones to see if it lowers preoperative anxiety.

  Recruiting Columbia University · New York, New York · NCT07845695

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.